Free Newsletter
Roche to Dr. Reddy's: Back off Boniva
Roche has no intention of letting Boniva go gently into that generic night. On the heels of a patent-infringement suit against Teva last week, Roche has sued Dr. Reddy's Laboratories over the osteoporosis drug. And this after acting against Boniva copycats from Apotex and Mutual Pharmaceutical in recent weeks.
Dr. Reddy's has filed for FDA approval for its version of Boniva, but Roche claims the drug is covered by one patent or another through 2023.
- read this article from India Infoline!--
d(["mb","\u003cbr\>
Related Articles:
Roche, Teva square off in Boniva patent fight. Report
Injectable Boniva approved. Report
Researchers tout once-monthly Boniva data. Report
Roche, GSK outline head-to-head trial of Boniva, Fosamax. Report
More stories about Roche Eli Lilly FDA approval Sun Pharmaceuticals lawsuit Generic drugs ADHD Teva Pharmaceutical
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: